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Abstract 
Background: The last two decades have come up with some important progresses in the genetic, immune, histochemical 
and bio (nano)-technological domains, that have provided new insight into cellular/ molecular mechanisms, occurring in the central 
nervous system (CNS) - including in spinal cord - injuries.  
Methods: In previous works, emerging from our theoretical and practical endeavors in the field, we have thoroughly 
described the principal intimate propensity and the pathophysiological processes - representing intrinsic limitations for self-recovery 
after SCI, and, at the same time, subtle targets for neuroprotection/ recovery - and reviewed the main related worldwide-published 
reports. The aim of this paper is to emphasize the connections between such main aspects and some feasible integrative solutions, 
including the ones for clinical practice.  
                Results: Consequently, we stress upon some therapeutic suggestions regarding this subject matter by systematizing the 
most up to date and efficient ones - obviously, within major limits, according to the very low capacities of CNS/ spinal cord (SC) to 
post-injury self preserve and recover. Moreover, we also talk about accessible drugs, respectively those being already in clinical use 
(but at present, mainly used to treat other conditions, including the neurological ones) and hence, with relatively well known, 
determined effects and/or respectively, restrictions. 
Discussions: The recent advances in the knowledge on the basic components of the afore mentioned CNS/ SC 
propensity for self destroying and inefficient endogenous repair mechanisms in the actual new context, will hopefully be, from now 
on, more effectively correlated with revolutionary - mostly still experimental - treatments, especially by using stem cells within tissue 
engineering, including, if needed, more advanced/ courageous approaches, based on somatic cell nuclear transfer (SCNT).  
Conclusions: This paper contains the scientific motivated highlighting of some already available drugs, ”neuroprotective” 
(and not only) properties too, which enable practitioners with (although not yet capable to cure - but anyway) more efficient 
therapeutic means, to approach the extremely difficult and still painfully disappointing domain, of spinal cord injury (SCI). 
Background. SCI current data. Actual context 
The closest to reality and updated statistics data, 
including the data with respect to SCI, are to be found in 
the United States of America (USA - that is why, below we 
present a few more details, mainly of this provenance). 
Yet, even there, probably because it refers to a very long 
lasting unsolved problem, there have not been any overall 
incidence studies on SCI since the 1970s and hence, it 
cannot be known precisely whether the incidence has 
changed lately [1].  
Anyway, an estimated rate of 2.5 million people 
live with SCI, with more than 130,000 new injuries 
reported each year worldwide [2].  
There were between 229,000 and 306,000 
(estimated to be approximately 250,000 - 259,000) 
persons, alive, in USA, in 2008, having SCI (52% of the 
spinal cord injured individuals are considered paraplegic 
and 47% quadriplegic), with an incidence (see the above-Journal of Medicine and Life Vol. 3, No.3, July‐September 2010  
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mentioned comments) of approximately 11,000 - 12,000 
(40 cases per million population - 0.04‰) additional 
people, yearly. Until 1979, the average age at injury was 
of 28.7 years, as the median age of the general 
population of the United States (likewise, more or less, 
practically, worldwide) has increased with approximately 8 
years, from the mid-1970’s. Moreover, the average age at 
injury has also steadily increased accordingly (31 years 
somewhere in the first part of a three decades period) 
over time. Since 2005, the average age at injury has been 
of 40.2 years. Currently, 80.9 - 82 % of the SCI occurred 
among males [3,4].  
It is appreciated that in the member states of the 
Council of Europe there are at least 330,000 subjects with 
about 11,000 new cases every year. Approximately 40% 
to 50% of these injuries are the result of road accidents 
and mostly occur at a young age [5]. 
Statistics on chronic patients with SCI in 
Romania, as in most other countries, are very difficult to 
compile and update (due to practical difficulties in 
maintaining a central database of case histories). 
However, we succeeded to quite satisfactory assess (just) 
their incidence (and only to approximate prevalence). 
Hence, according to our last query of the Diagnosis 
Related Groups (DRG - the Australian classification) the 
National database of inpatient care [6], we have found, in 
2008, 419 new cases of hospitalized patients with SCI, 
accounting for an incidence of 0.0194‰. Subsequently, 
we could estimate the total number of such patients in 
Romania to be around 15,000-20,000 +/- a few 
thousands. The average age was of 41.4 years [7].                                                                                                                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCI usually generate severe and rather 
permanently, loss or impairment of basic functions, such 
as: voluntary/ active mobility, sensitivity, micturition and/or 
defecation control, erection/ ejaculation/ fertility [9-12]; 
therefore, they are, in most of the cases devastating, 
especially because they are frequently irreversible. 
On long-term or (quasi)continuously, they are 
usually associated with serious co-morbidities, emerging 
from: tissue distrophicity (mainly pressure sores), urinary 
tract infections (UTI - chronic/ recurrent), metabolic and/or 
(including related) circulation disturbances: of blood 
pressure [13], respectively of the venous-lymphatic flow in 
lower limbs especially the anti-gravitational one [14]. 
  SCI can be divided into two main types of 
lesion/ functional damages, i.e. complete and incomplete. 
Complete  means there is no function/ control 
below the neurological level of injury: no sensations and 
no voluntary movement is preserved (including) in the 
sacral segments S4,5. 
 Incomplete  SCI  means there is some 
functioning below the injury level. Such a person may feel 
parts of the body that cannot be moved, including the 
sacral segments S4,5 (type B on the American Spinal 
Injury Association Impairment  Scale - AIS B) or have 
some active motility/ functional control preserved too (AIS 
C, D) [9], on both sides of the body. In fact, the segments 
at which the normal function is found, often differ 
according to the side of the body and in terms of sensory 
vs. motor testing; (thus, up to four different segments may 
be identified in the determination of the neurological level, 
i.e.: R-sensory, L- sensory, R-motor, L-motor. In such 
cases, it is strongly recommended that each of these 
segments is separately recorded). When a single 
(average /global/ synthetic) “level” is used, the term 
Sensory Level refers to the most caudal segment of the 
spinal cord with (quasi) normal sensory function on both 
sides of the body, similar to the Motor Level [10]. 
The effects of the SCI essentially depend on the 
spine/(al) cord topographic level of the injury, too - i.e.: 
paraplegia, after thoracic and/or lumbar and respectively, 
tetraplegia (from all points of view: generally biological - 
having also a life threatening  potential, especially during 
the acute and sub-acute phases post injury - and 
functional, including: self care/ autonomy, family relations, 
work and social activity/ participation, quadriplegia is by 
far more serious than paraplegia, being in fact, one of the 
most severe and invalidating sufferings within the human 
pathology), following cervical,  SCI. 
Usually, post injury, no significant regenerative 
processes naturally occur in the CNS, including the SC: 
conversely, there are strong intrinsic hampering; (para) 
physiological and pathological processes that prevent 
spontaneous recovery, thus explaining the still poor 
therapeutic/ rehabilitative outcomes, obtained in the 
approach of these conditions. 
Actually, the SCI treatment is generally limited to 
surgical intervention - decompression, drainage and 
stabilization - and to complex (supportive and assistive) 
care, intricated with long-term rehabilitation programs and 
respectively, follow-up.  
Fig.1 The spinal column and the essential muscles and 
somatic/ visceral functions depending on the spinal cord 
and nerves, at corresponding metameric levels - by [8] Journal of Medicine and Life Vol. 3, No.3, July‐September 2010  
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Still, after the 1990's, the advances in medical, 
surgical and rehabilitative technologies, significantly 
improved the length and quality of life for people with SCI. 
Because there is no cure for SCI and its devastating 
sequels, many researchers are addressing this matter 
and subsequently, there have been progresses in the 
laboratory. However, none of them succeeded, to produce 
radically effective healing outcomes expected/ long 
awaited by the patients, until now, i.e. to spectacularly 
improve the neurological/ functional outcome.  
Currently, as already mentioned, there are no 
effective therapies for SCI, except for the partially 
prevention of further, extending  post injury, damages: 
neuroprotection/ pleiotropic (a quite rare property, specific 
to neurotrophic factors - fulfilling both, neuroprotection 
and neuroplasticity stimulation) and - possibly, at best - 
for some multimodal (i.e. including neurotrophicity and 
neuro/ synaptogenesis), effects [1,15, 16]. 
  At present, the Obama Administration of the 
USA has compared a radically different opinion regarding 
the new biotechnological researches to the former one, 
i.e. a very supportive one. Hence, aside a very generous 
unprecedented high budget allocated for research and 
development  [17] it has recently also changed the 
composition of the American Bioethics Commission - that 
will move beyond the issues that consumed the previous 
panels, such as stem cells and (therapeutic) cloning. [18]. 
Hence, almost one year ago, the President of the 
USA, Barack Obama, officially declared - and acted this 
way:  
”Today, with the Executive Order I am about to 
sign, we will bring the change that so many scientists and 
researchers, doctors and innovators, patients and loved 
ones have hoped for, and fought for, these past eight 
years: we will lift the ban on federal funding for promising 
embryonic stem cell research. We will vigorously support 
scientists who pursue this research. And, we will aim for 
America to lead the world in the discoveries it may yield 
one day. 
At this moment, the full promise of stem cell 
research remains unknown, and it should not be 
overstated. But, scientists believe these tiny cells may 
have the potential to help us understand, and possibly 
cure, some of our most devastating diseases and 
conditions. To regenerate a severed spinal cord and lift 
someone from a wheelchair. To spur insulin production 
and spare a child from a lifetime of needles. To treat 
Parkinson’s, cancer, heart disease and others that affect 
millions of Americans and the people who love them. … 
However, in recent years, when it has come to stem cell 
research, rather than furthering discovery, our 
government has forced what I believe it is a false choice 
between science and moral values. In this case, I believe 
the two are not inconsistent. As a person of faith, I believe 
we are called to care for each other and work to ease 
human suffering. I believe we have been given the 
capacity and will to pursue this research - and the 
humanity and conscience to do so responsibly” [19]. 
Therefore, a most important, general - at least 
intermediate - message for all post SCI para- and tetra-
plegics to take home, is to remain, according to the well-
known - old but more and more actual World Health 
Organization (WHO)’s definition of a complete state of 
health - as healthy as possible (physically, mentally, 
socially) and active: in family, professionally and ad 
vocationally.  
Integrative emphases regarding limits, 
detrimental pathways and related targets 
for neuroprotection/ recovery, in SCI 
 Herein we (re)emphasize that there are morpho-
functional, inner, restrictions of the CNS/ SC’s post injury 
self-repair „skills”, within a reactive behavior prone to self-
augmenting pathological, destructive processes, which 
result in vicious circles, in further limitations (mainly: 
neurons, lacking centrosoms, cannot reproduce/ 
regenerate; there are pre-formate pathways, which, from 
yet unknown reasons, exert active opposition to axonal 
re-growth) and that these intrinsic, misfortunate, ”brakes” 
to self-recovery and respectively, propensity to 
detrimental evolutive pathways, are the principal actual 
targets for neuroprotective/ pleiotropic (possibly even 
multimodal) therapies, in order to reduce, as much as 
possible the ”secondary injuriy(es)/ lesion(s)/ damage(s) 
processes’/ events’ cascade” and consequently, to obtain 
better further recovery/ rehabilitation [1,15]. 
CNS injuries may be divided into two main 
categories: primary - which occur (mainly) at the moment 
of a trauma - and secondary ones, that develop after the 
initial injury.  
The mechanisms of “primary injury” are not yet 
completely understood; however, (including relatively) 
intense - which is frequently the case - SC contusion (not 
physical trans-section) produces, from the morphological 
point of view, a central hemorrhagic necrosis - the 
“epicenter” of the initial SC lesion - surrounded by 
disrupted and respectively - farther - surviving axons, with 
centrifugal distribution [1] 
The cascade of pathophysiological events 
leading to secondary damage, is quite similar in traumatic 
(and also ischemic) injuries, of both the brain and the SC 
and therefore, neuroprotective/ pleiotropic (possibly even 
multimodal) therapies are, in many respects, resembling 
[1,15] 
Still, there are structural non-similarities, 
resulting in different responses to traumatic insults 
between  SCI and TBI: SC - crucial tracts are placed 
closer to the dural surface (superficial) . As far as the 
brain is concerned - deeper structures are often the 
critical ones. Journal of Medicine and Life Vol. 3, No.3, July‐September 2010  
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Secondary damages develop after the initial/ 
primary injury - as a consequence of a complex, rather 
specific pathophysiological events ”cascade” to CNS/ SC, 
and produced within vicious circles - in the affected area 
and its neighborhood - effects that may continue for a 
long time [1,15]. 
The secondary injury processes, briefly consist 
of: excessive synthesis of nitric oxide (NO), harmful 
metabolic hyperactivity - including/ conjugated with 
(mainly) phosphodiesterase 4 mediated myelin-
associated Neurite (Out)growth Inhibitor (protein, called 
NOGO-A). The indirect stimulation presupposes the 
activation of its receptor results in the depletion of a 
cellular cyclic adenosine monophosphate (cAMP), i.e. in 
dramatically disturbance/ depletion of cell energetics - and 
oxidative stress, microglia activation and microglia-related 
cytokine unbalance, immune shifts and local 
inflammation, (including through prostaglandins’ 
chemotactism - enhancing local inflammation and also, 
secondary, local/ regional vasoconstriction/ ischemia) the 
alteration of the regional (micro) circulation - including the 
cerebro-spinal fluid, with blood-brain (haemato-nevraxial) 
barrier dysfunction- electrolyte disturbances - resulting in 
nervous tissue swelling,  including massive edema  - 
followed (because of suddenly installed osmolysis) by cell 
induced necrosis and “delayed mechanisms of cell death” 
- apoptosis and apoptosis-like processes - lead, in sum - 
cumulated with the primary ones - to severe/ (most of 
them) irreversible, consequences: neuronal necroses and 
apoptoses, demyelization, scar and cyst formation, 
disruption of morpho-functional nerve pathways/ 
disconnection (Figure 2), deliverance of “specialized” 
molecules in active, pre-formated, block of axons’ re-
growth [1,15,20,21]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The secondary events’ ”cascade” entail an 
extremely complex and extended reaction, practically of 
the entire affected body:  from its gene level to the 
”macroscopic”/ clinical, one.  
So, in order to obtain efficient neuroprotective/ 
pleiotropic/ multimodal therapeutic results and thus - 
maybe, even - a future cure, as many as possible 
(eventually - the whole picture) of its intimate, necessary 
to be approached, items/ targets had to be known: the 
ones to be counteracted, the others to be promoted.  
Hence, many molecules expressed by 
heterogonous glial and neural subpopulations of cells 
have been identified, which are directly or indirectly critical  
for tissue damaging/ sparing/ re-growth inhibiting/ 
promoting, angiogenesis, neural plasticity, and also, 
various substances/ energy vectors with neuroprotective/ 
biotrophic and/or regenerative properties, as mentioned in 
previous articles[1,15].  
More specifically, the secondary injury 
processes’ cascade, at cell/ molecular level, mainly 
includes about 18 pathways (in the near future their type 
and consequently, their number, could change, as the 
researches in this fascinating field are intensely 
progressing). According to the state-of-the-art, we have 
already systematized them into a detailed presentation 
[15]. 
Yet, for a better understanding - and this is one 
of the aims of the present paper - some further 
specifications/ details are necessary, as from objective 
reasons, concerning previous related works, there have 
been (and will always be) editorial space constraints.  
Hence, so as to identify and achieve integrative 
connections with the clinical practice as efficient as 
possible, a stress has to be made upon some of the 
principal - especially by their quantitative amplitude/ 
extension and subsequently, contribution to the overall 
post SCI damage -  intimate pathological processes 
involved, i.e. the: oxidative stress, based on an imbalance 
between a very high increase of oxygen reactive species 
(ORS) production (including serum iron/ labile Fe pool, 
mediated - Fig. 6) and down regulation of antioxidant 
systems’ amount/ effectiveness; disimmune and 
diselectrolitic mediated tissue disorders, including the 
ones of the local/ regional microcirculation - resulting in 
ischemia and edema (the latter leading, by osmolysis and 
cell passively die off to necrosis - thus to cell loss - 
augmented by conjugated destroying actions of ORS, 
endogenous enzymes, with ”digestive” actions on the 
main kinds of biological membranes’ compounds (protean 
and lipid); excess of neurotransmitters (more complex - 
especially, glutamate - and also some chemically simple 
ones - but equally dangerous - such as calcium ions); last 
but not least - different complicated pathways/ processes 
of apoptosis [15].  
More detailed, main ORS are the following: 
superoxide anion (O2-), hydroxyl anion (OH-), hydrogen 
peroxide (H2O2) and peroxinitrite (ONOO-) .  
Critical concentrations of NO, together with - by 
increased Ca2+ cellular influx - activation of neuronal nitric 
oxide-synthase (nNOS), - again - in the presence of Ca2+ 
(absorbed at the mitochondria level) convert NO into 
ONOO-: one of the most “active”/ horrid  ORS. Moreover, 
the intense toxicity, inflammation (by alterating 
mechanisms of gene transcriptional factors type - 
Fig. 2 Late post traumatic SC cyst/ syrinx, ”based on” 
acute/ initial central hemorrhagic necrosis - by [22] Journal of Medicine and Life Vol. 3, No.3, July‐September 2010  
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resulting in stimulation of pro-inflammatory cytokines’ 
production) triggering capacity and pro-apoptotic actions 
of ORS [15], are known.  
Additionally, other by-products of the post SCI 
secondary injury pathways - also dreadful endogenous 
tissue ”poisons” - are the unsaturated aldehydes (end 
compounds of lipid peroxidation, that also result in higher 
quantities, during oxidative stress), mainly: Acrolein  [2-
propenal/ Acr(yl)aldehyde (C3H4O) - highly electrophilic, is 
one potential mediator of secondary damage, being 
capable of diffusing from compressed tissue to the 
adjacent, otherwise uninjured, ones – [23] and 4-
hydroxynonenal [trans-4-hydroxy-2-nonenal or 4-HNE 
(C9H16O2) - that has been hypothesized to play a key role 
in cell signal transduction in (thus affecting) a variety of 
pathways (from cell cycle - in a concentration-dependent 
manner - to cellular transfection and adhesion events), 
interfering - including - with induced by oxidative stress 
apoptosis (through its regulation of mediated signaling) by 
a crucial (neuro)protective antioxidant endogenous 
enzyme system: of glutathione’s/Glutathione S-
transferases (GSTs) – [24].  
               Aside their direct and indirect toxicity, all these 
by-products, including components of the dead or dying 
cells (injury to the spinal cord results, histological,  in 
damaged: neurons, glial cells, blood vessels and 
meninges; moreover, cellular debris at the injury site 
contains numerous molecules that potentially inhibit 
regrowth of neurons) [25], stimulate glial reactions, in 
principal the astrocytes’ signaling up regulation of 
colagenous production/ gliosis (together with -including of 
cytoskeleton/ lipid breakdown ones - metalo-proteinases), 
the release/ activation of cytokines - attracting 
inflammatory: cells, prostaglandins (including transforming 
growth factor TGFβ (TGF-β1 and TGF-β2 - both isoforms 
contributing, complementary, in the formation and 
respectively, in the maintenance, of glial scars) [26] and 
of leucotrienes - thus adding more inflammation/ cell 
death and consequently, fibrosis, to previous detrimental 
pathways in reactive/ compensatory manner: ”fill the void 
(with connective, non-parenchyma, tissue) … fulfill   
irreversibility” - all resulting, including in scars - one of the 
major causes (aside non-replaceable loss of neurons) of 
the limited/ practically inefficient CNS/ SC self repair, post 
injury behavior (Figure 3). 
To this misfortunate result, also other chemical/ 
physical complex inhibitory barriers for re-growth of the 
disrupted axons across the lesion site, seem to strongly 
contribute: Ephrine (EphA4), Glial Fibrillary Acidic Protein 
(GFAP) [1], Vimentime and respectively, the own myelin 
sheath. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additionally - but basic/ intrinsic - in the CNS/ 
SC, from reasons yet unclear, there are  strong ”active” 
inhibitory molecules/ processes, mainly to the 
(spontaneous, initial post-injury tendency) of axonal re-
growth and - supplementary - of CNS cells’ regeneration, 
generically called the "braking" machinery in neurons: 
tightly related to NOGO/(NgR (Nogo protein Receptor) 
proteins and more generally, to the Rho (superfamily of 
”Rho-dopsin gene - including neurotransmitter - 
receptors”) signaling pathway [1]; this receptors  family 
relays on a protein called TAJ or TROY and  on another 
one, p75, that act both, as important part of the same 
family of receptor complex proteins (called TNF 
receptors), on neurons, by responding to growth-inhibitory 
molecules in myelin and thus, preventing the cable-like 
axons’ (re)-growth of injured neurons in the CNS/ SC: 
acceptance of  these  inhibitory molecules, like a key 
fitting a lock and switched-on, results in inhibitory 
signaling, within the neuron [15]. Rho kinases (ROCKs) - 
the first Rho effectors to be described - are serine/ 
threonine kinases that are important in fundamental 
processes of cell: migration, proliferation and survival. 
Abnormal activation of the Rho/ ROCK pathway has been 
observed in various disorders of the CNS. Injury to the 
adult vertebrate brain and/or SC, activates ROCKs, 
thereby inhibiting neurite growth and sprouting. 
Conversely, the inhibition of ROCKs results in accelerated 
regeneration and enhanced functional recovery after SCI 
in mammals; moreover, inhibition of the Rho/ ROCK 
pathway has also proved to be efficacious in animal 
models of stroke, inflammatory and demyelinating 
diseases, Alzheimer's disease and neuropathic pain. 
Therefore, ROCK inhibitors, have the potential to prevent 
neurodegeneration and to stimulate neuroregeneration in 
various neurological disorders [28], thus being important, 
subtle targets, for neuroprotection. When these molecules 
bind to receptors on the surface of damaged neurons, 
they trigger an intracellular pathway, i.e. of the Ras - Rat 
Fig. 3 Glial/ fibrous collagen, scar formation: green-
nerves; red-scar - by [27] Journal of Medicine and Life Vol. 3, No.3, July‐September 2010  
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sarcoma - a superfamily of (first identified as transforming 
onco)genes, comprising of over 150 human members [29] 
and divided into eight main families, each of which is 
further divided into subfamilies: Ras, Rho, Rab, Rap, Arf, 
Ran, Rheb, Rad and Rit. Miro (a recent contributor to the 
superfamily) - homolog gene family, member A: (RhoA)-
Rho-associated, coiled-coil containing protein kinase 
(ROCK) pathway - that irreversibly inhibits neurite 
sprouting and regeneration [25].   
              Regarding  the  apoptosis  (Figures 4,5,6), 
including for neurons, the growing amount of knowledge 
concerning its subtle processess (especially sequential 
activation of key-role genes: p53, Bax, Endonuclease G - 
EndoG and its relation with the oxidative stress), it is 
mandatory - including for allowing some new both, 
conceptual and practical advances - to more precisely 
know and consequently, therapeutically target, the crucial 
end points within such of these pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 The caspases pathway of apoptosis - cited by [30] 
Fig. 5 Activation of calpains - within the calpains pathway of apoptosis Journal of Medicine and Life Vol. 3, No.3, July‐September 2010  
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As above evoked (in relation to apoptosis) 
another subtle complex - and major, as well - of 
determinants (including) for post SCI reaction pathways, 
are the gene expression related changes - objectified by 
spatial and temporal profiling. 
Therefore, micro array technology was used to 
identify functional groups of genes that are differentially 
expressed/ regulated, following contusive injury of adult 
rat spinal cord, at 3 h, 24 h, 7 days and 35 days; there 
were thus identified, including those associated with: 
apoptosis, cell cycle, inflammation and cholesterol 
metabolism. This endeavor could lead to identification of 
novel potential therapeutic targets within each group of 
examined genes [32]. 
In a suggestive/ metaphoric statement, the 
figurative linkage of events in SCI can be synthesized as 
follows: 
-  brutal aggression - “illegitimate occupation of 
territory” - by the direct trauma/ primary injury  
-  “terror by the occupation troops, upon civil 
(i.e.: initially non-affected, by the primary injury, tissues) 
population” - of the secondary lesions    
-  “guerrilla resistance/ sabotage” - against   
natural regeneration - of the inner (also natural) inhibiting 
factors. 
      Hence,  regarding  prognosis, the secondary 
injuries are the cross road between regaining functional 
status and falling into severe, (life-) long-term disability. 
Therefore, trying to aim as many as possible of 
the afore mentioned  targets - secondary injuries and their 
subsequent disastrous consequences - modern research, 
including experimental approaches in SCI, focus on 
several intricate, rather overlapping, therapeutic 
objectives and means/ interventions, such as: 
neuroprotective, neurotrophic, neurorestorative, 
neuroreparative, neuroregenerative, neuro(re)constructive 
and  neurogenetic. The first three of these therapeutic 
directions are generically assimilated as neuroprotective 
[33,34]. 
Integrative emphases - clinical/ 
therapeutic connections 
In our article reviewing the main published 
reports on neuroprotection in SCI, we have presented a 
synthetically/ systematized, yet quite exhaustive, list (and 
related  details/ comments) of therapeutic means - 
pharmacological and/or and procedures - considered to 
have, more or less, neuroprotective properties in spinal 
cord and brain injuries, within a ”color code” [1]. 
Herein, we stress upon some practical 
suggestions to approach this subject matter, emphasizing 
the most, to date, efficient - obviously, within major limits, 
according to the afore mentioned very low capacities of 
CNS/ SC to self preserve and recover - and accessible 
Fig. 6  Factors and mechanism, stimulating and inhibiting, oxidative stress - by [31] 
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drugs, respectively those that are already in clinical use 
(but at present, mainly to treat other - including also 
neurological - conditions) and therefore having relatively 
well known, determined, effects and/or restrictions. 
In this respect, there are to be mentioned [1]: 
 
  - anti-inflammatory/ immune modulators, 
including: steroid anti-inflammatory drugs (SAIDs), non- 
steroid anti-inflammatory drugs (NSAIDs), piritinol  
  - neurotropic vitamins and other nutritional 
supplements (B vitamins, tioctic acid, selenium, zinc, 
magnesium - including for the last one’s non-competitive 
anti-NMDA receptors action), lithium (also with anti-
inflammatory actions - reduces microglia and macrophage 
activation - by affecting the post transplantation of neural 
progenitor cells (NPCs), host immune response, in SCI 
adult rats) [35] 
- anti-oxidants/ free radical scavengers: beta-
carotene, ascorbate, alpha-tocopherol/ Triovit (A,C,E,), 
superoxide dismutase, melatonin, Q10 co-enzyme  
- iron chelators: deferoxamine/ Desferal (only 
alternatively and if there are no other non/ 
contraindications and/or restrictions/ risks, in the specific 
patient’s case); quercetin - including with cell cycle 
modulating effects, in combination with resveratrol, a 
syrtuin gene diacetilase -: Longevinex, Zen Tonic (the 
latter is the only drug of this kind inner marketed) 
- antagonists - directly or indirectly - of growth 
inhibitory signals and/or of cellular energy collapse 
(including post injury) in CNS/ SC: statins, , phospho-
diesterase inhibitors (methilxantines - theophiline tabletted 
medicines/ black, common, tea [36], used for hydratation, 
anyway -, Rolipram - used in the past, as an 
antidepressant - and respectively, Dibutyril cyclic AMP 
(the last two drugs - not yet inner marketed) 
- acrolein antagonists: Acetylcysteine/ N-
acetylcysteine (ACC, Fluimucil, etc.), mainly a mucolytic 
agent - synergistic, but by different mechanisms, with 
theophiline, on improving bronchial air flow - is usually 
necessary/ administrated in post SCI patients, in acute, 
sub-acute and/or sub-/hyper-chronic [37] stages (mainly 
in tetraplegics, that often have breathing troubles, due to 
the high level of the neurologic impairment, but in some of 
the paraplegics, too - especially in the first weeks/ months 
after spine surgery, when they have to keep strictly a 
declive position). ACC acts, on one hand, as an 
antioxidant, by augmenting the glutathione reserves and 
on the other, like an  antidote drug, counteracting 
acrolein, similarly with mesnum (Mesna) - likewise for 
their (also) common mucolytic effect [38,39]   
-  neurite outgrowth promoters (nucleosides: 
Leteprinim, Keltican/ Nucleo forte - not yet inner 
marketed) 
-   substances with neurotrophic actions: peptide 
mixtures (Cerebrolysin, Actovegin) and more recently, a 
chemically simple one, Lhitium (chloride, although 
carbonate is its more available for current clinical use, 
chemical/ pharmacological conditioning) has been shown 
to exert robust neuroprotective effects: stimulator of 
neurotrophic factors discharge (significantly increase the 
Nerve Growth Factor - NGF - concentrations, but only in 
some parts of CNS - especially in the brain) [40]; neural 
stem cells protector/ differentiation promoter  (the 
treatment of, including transplanted [35], NPCs with 
lithium - also a specific inhibitor of glycogen synthase 
kinase 3beta/   GSK3beta - aside its afore mentioned anti-
inflammatory effect, significantly suppresses apoptosis of 
NPCs) [41];  elicitor of NPCs’ differentiation/ increased 
neurogenesis facilitation [42] in CNS/ SC - through both, 
resembling mechanisms and unevenness manner 
(systemic application  of the GSK-3 inhibitor: lithium to 
spinal cord-lesioned rats, suppresses the activity of this 
kinase, around lesion and induces significant descending 
corticospinal and serotonergic axon sprouting, in caudal 
spinal cord and promote locomotor functional  recovery, 
GSK-3 signal thus being an important therapeutic target 
for promoting functional recovery of adult CNS injuries) 
[43]. All of these relatively recent traced actions - apart/ 
different from lithium’s well known mood-stabilizing effects 
in humans - are neurotrophin ”like”, i.e. of pleiotropic/ 
(even) multimodal kind - but for the moment, lithium 
administration in SCI should be considered only 
alternatively and if there are no other non/ 
contraindications and/or restrictions/ risks, in the specific 
patient’s case (see further)  
-  apoptosis inhibitors: Minocycline (not inner 
marketed), Erythropoietin/ rHuEPO (only alternatively and 
if there are no other non/ contraindications and/or 
restrictions/ risks, in the specific patient’s case) or - 
seemingly with less risk for administration - Erythropoietin 
carbamylate (not yet marketed)  
-  anti-excitotoxic agents (glutamate blockers) – 
fig 7: of ionotropic receptors - NMDA (N-methyl-D-aspartic 
acid) - competitive (Selfotel) -, non-competitive 
(Memantine/ Ebixa, Amantadine, Dextropophan - not yet 
inner marketed -, but mild, better/ to be chosen for 
neuroprotection post SCI: Cerebrolysin, Magnesium) - 
AMPA (α-amino-3-hydroxyl-5-methyl-4-isoxazole-
propionate) non-competitive (Phenytoine - only 
alternatively and if there are no other non/ 
contraindications and/or restrictions/ risks, in the specific 
patient’s case) Journal of Medicine and Life Vol. 3, No.3, July‐September 2010  
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- riluzole, a glutamate release inhibitor/  sodium 
channel blocker, with antiexcitotoxic effects, - already 
registered for the treatment of amiotrophic lateral 
sclerosis - showed, in rats: significant improvements of 
neuronal sparing/  survival and reinnervating capacity, 
after SCI, of injured motoneurons, not only when the 
treatment started immediately after injury but also in 
cases when riluzole administration was delayed for up to 
10 days [44] and also was found to improve mitochondrial 
function, with enhancement of glutamate and glucose 
uptake (Methil Prednisolone - MP - treatment was found 
to reduce lipid peroxidation, but also improved glutamate 
and glucose uptake, the treatment combination: Riluzole + 
MP was found to be effective in improving all five 
measures of oxidative stress in SCI rats - contusion type) 
[45]; in rabbits, riluzole was found to prevent neuronal 
necrosis and apoptosis and cytoskeletal proteolysis and 
also, to really and consistently be able to prevent SC 
damaging, after experimental induced SC ischemia [46]; 
in humans, there are yet, insufficient controlled trials to 
support, based on statistically significant and reliable 
data, the numerous and very important beneficial effects - 
within an integrative perspective, with combined 
neuroprotective strategies and approaches [47] - of this 
drug with seemingly, overall neuroprotective/ (even 
multimodal ? - o. n.) e\ctions; therefore, a group of 
researchers have recently (July 2009) started a multi-
centre study (USA, Canada) concerning: ”Safety of 
Riluzole in Patients With Acute Spinal Cord Injury” 
(estimated enrollment: 36 acute SCI patients - less than 
12 hours since injury -; study start date: July 2009 - but 
the study is not yet open for participant recruitment, last 
updated: July 6, 2009 -; estimated primary study 
completion date: April 2011 - final data collection date for 
primary outcome measure -; estimated study completion 
date: October 2011) [48]. Hence, considering, on the 
other hand, its possible important side effects (especially 
neutropenia and/or liver toxicity) we consider it preferable 
to wait for some serious clinical trials to be carried on, 
previous to administrate riluzole in SCI affected 
individuals (actually, this is a permanent, general problem, 
regarding introduction of a novel therapy in supra/ acute 
stages of SCI: psychologically, the patients accept it 
rather difficult, as they still strongly hope in a vigorous 
spontaneous recovery and - even doctors - can not be 
sure, in many cases, if administration of a new drug 
couldn’t do more harm to the, SCI evolution, than help it, 
or simply, just to have any effect at all) 
- (possibly/ limited indication) neuro-restoratives 
agents: 4-Aminopyridine/ Fampridine - a relatively 
selective blocker of voltage-activated potassium channels, 
which has been studied for its capacity to restore 
conduction in injured nerves including after SCI - not yet 
inner marketed  
-  calcium channel blockers (the rationale for 
their, hopefully neuroprotective, use during the acute 
phase of SCI was, on one hand - directly - to lower the 
intracellular calcium enhanced influx/ accumulation and 
on the other - indirectly - to increase micro-vascular 
permeability, thus diminishing ischemia and edema; but, 
Fig. 7  Schematic synthesis of glutamate main effects - and consequently, of its blockers 
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the most serious limitation of the calcium channel 
blockers use in SCI, is represented exactly by the arterial 
hypotension - afore mentioned, ischemia generating, with 
its redoubtable complications - they produce, which 
counteracts the anticipated effect of increasing the SC 
blood flow): nimodipine - a voltage-operated „L” channel 
blocker - has provided, after its administration in studies 
on animal models, in the acute and chronic phases of 
SCI, various - mostly disappointing - conclusions, i.e. 
while some authors found it to decrease axonal 
morphological damage [49]  and to improve SC 
conduction, most researchers found no beneficial effects 
of this therapy [50,51].    
Discussions 
Aside the conceptual and general context/ trend 
related considerations, already exposed within the 
discussion part of the summary, herein we add some 
practical - arising, including from an own consistent 
experience of integrating/ confronting scientific highest 
standards/ rigors with daily clinical practice and human/ 
natural pressure, mainly from the patients ”and the people 
who love them …” [19] -  comments:  
    -  there are not yet enough precise 
investigational data regarding all the above presented 
drugs’ pharmaco-dynamic behavior, including their 
capability/ amount of  crossing the hemato-nevraxial 
barrier and hence, their real therapeutic contributivity to 
the clinical complex approach of SC/ CNS injuries (we 
consider this subject matter to be a further research item 
on our agenda, although rather difficult to scientically/ 
methodologically be approached) is unclear, from an 
Evidence Based Medicine (EBM) prospective. Moreover, 
the ability of a certain drug to cross the hemato-nevraxial 
barrier and to be effective in some CNS disturbances/ 
clinical conditions, does not automatically give it the 
possibility to exert true therapeutic effects in SCI, too: the 
quite intense (especially in the recent years - see above) 
studied lithium, for the many pathways it is targeting, with 
very important beneficial effects - but identified only in cell 
cultures and animal models, not in the clinical use - 
although it can enter including the CNS, this drug hasn’t 
shown significant results in humans; as a matter of fact, 
according to a very recent and rigorous trial [52], lithium, 
systematically administrated up to 6 months, has provided 
no improvement in chronic post SCI cases, except only 
for neuropathic pain - in patients having such symptoms 
(probably this action is mainly based on its classic, 
antidepressant properties) 
Regarding the afore given for guidance drugs - in 
clinical use - for acute, sub-acute and/or sub-/hyper-
chronic post SCI cases, within combined formula(e), in 
purpose to provide as efficient as possible, pleiotropic/ 
(even) multimodal effects - it exist opinions according to 
which, as long there are not enough reliable controlled 
trials (for many/ most of them) to objectively prove their 
are effective, their use should be discouraged; strictly, 
from the afore evoked EBM prospective, such an attitude 
seems right; but, until all the huge number of medicines in 
clinical use nowadays, will be evaluated, each one 
through several controlled and rigorous trials - a 
hypothetic and practically impossible to be fully achieved, 
in a predictable future, desideratum - SCI patients appear 
every day and desperately ask for solution(s) to their 
tragedy; under these circumstances/ generally moral-
deontological pressure, what should professionals choose 
to do - taking into account that such, afore exposed, 
modern therapeutic options, are drugs already tested for 
safety (otherwise they could not be legally allowed on the 
pharmaceutical market) and - at least partially - for 
efficacy, too and furthermore, that  many of them 
(increasing in number, lately) has been (dis)graded to the 
OTC (Over - The - Counter) category, i.e. according to 
rules, they are available on the pharmaceutical market 
even without a special medical recommendation (as it is 
well known: this doesn’t mean they are useless, but they 
have relatively well determined both, beneficial actions 
and respectively, mainly - limited - adverse effects/ risks/ 
restrictions, administration related). 
Our many clinical observations/ expertise in this 
domain, allow the ascertainment that, although not 
spectacular - especially concerning motor recovery - 
approaching  post SCI cases by the exposed, multi-
targeted pharmacological combinatory (partially 
individually tailored) formula, provides - aside the 
improvement of long-term, general health state/ survival, 
by, including, less complications - at least, a better 
compliance of such patients: it is not much but definitely is 
more than to act strictly through the EBM prospective, i.e. 
to administrate, every new SCI person almost nothing, 
aside supportive general therapy - if/ when needed (to say 
no things about his/  her  psychological reaction/ mood 
and further, motivation to cooperate in long-term 
rehabilitation programs, when told that practically, there is 
nothing to be done for treating SCI) 
-  before introducing the last comment - which is 
strictly medical, subject related - it is to be underlined that 
generally, acquiring many new(est) knowledge, of cellular/ 
molecular level, enables physicians to target ”deeper”/ 
more intimate/ subtle pathological layers, thus optimizing 
different existing therapeutic substances/ agents’ 
administration, by intelligently adding to their use 
(sometimes surprisingly different/ wider, respectively 
common) new/ (maybe even) unexpected, useful effects, 
beyond ”classical” indications - to be, at present, found in 
a drug leaflet or another      
-   although, as emphasized, to solve the tough 
problem of gliosis/ scars would be critical to achieve major 
therapeutic results, unfortunately, at present, there are no 
drugs/ (other) medical procedures - i.e. scar inhibitors - 
with such effective actions: the long awaited 
”Regeneration (? - o. n.) promoting treatment” (RPT) of 
patients with acute traumatic SCI, based on Cordaneurin: 
a new drug, focused on preventing scar formation in acute 
CNS/ SC - contusive model - damage (up to 3 days post 
injury), is still pending. This substance, expected to 
revolutionize (in preclinical tests, apparently there have 
been obtained promising results - Fig. 8) therapy in acute Journal of Medicine and Life Vol. 3, No.3, July‐September 2010  
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SCI, has yet granted, since 2004, Orphan Drug 
Designation by the European Medicines Agency (EMEA) 
for the indication: ”treatment of traumatic spinal cord 
injuries”; but, although Cordaneurin was initially 
scheduled to enter clinical trials in 2006 and to be 
launched on the market in 2008, at present, there seem to 
be still ongoing (2009/ 2010) clinical studies on it (… ?) 
and this product is still non-marketed. Aside Cordaneurin, 
the same biotechnological producer, claims possible 
achievement, in the relatively near future, of a more 
complex (and hopefully efficient ?) treatment: Cordaneurin 
in combination with Stromal cell-Derived Factor-1-gamma 
(SDF-1gamma); this chemokine is one of the key 
modulators in the development of CNS: SDF-1γ is a 
special type of immune modulator that (also) blocks 
substances which inhibit axonal (re)growth, thus acting for 
neuronal growth promotion - after, SCI; therefore, it 
seems to be strong evidence that chemokine SDF-1γ 
could be a synergistic drug for the treatment with 
Cordaneurin (? o. n.) [53,54] 
 
 
 
 
 
 
 
 
 
Conclusions 
Understanding deeper and deeper, both: 
intimate basis of the especial - and unfortunately very 
unfriendly - way CNS, including SC (even worse, as the 
latter has considerably fewer redundant cellular and 
connection availabilities - thus possibilities of 
”compensation by taking over” after aggressions) and 
respectively the mode different therapies are targeting,   
more or less effectively, some of these numerous and 
very complex pathways, on which relies the disastrous 
post injury consequences, has provided the specialists 
dealing with SCI, better instruments for neuroprotection 
and even more - for pleiotropic/ multimodal effects. 
While part of such drugs and/ or procedures are 
still experimental or in course of being clinical 
implemented, some others are already available (many of 
them used to date, in principal, for treating other, including 
neurological, conditions). 
Thus - and this was the main practical aim of this 
paper - scientifically motivated highlighting (also) their 
”neuroprotective” (and not only) properties, enable 
practitioners with, although not yet capable to cure, but 
anyway  with more efficient - compared to 1-2 decades 
ago - therapeutic means, to approach the extremely 
difficult and still painfully disappointing/ yet therapeutically 
poorly ”covered”, domain of SCI. 
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